Berobenatide vs VCT220
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Berobenatide
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)
Result source: NCT06712836
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) and partners
NCT06939296 · Phase 3 · completed
This was a randomized, double-blind Phase 3 trial with 840 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-05-18. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: March 2027 · NCT07652047 (registry estimate)
Reported efficacy
Percentage change from baseline in body weight (From baseline to week 34); The proportion of subjects with a body weight reduction ≥5% from baseline (From baseline to week 34): Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). (met)
Result source: NCT06939296
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | VCT220 |
|---|---|---|
| Body weight, % change | —Trial running · NCT07311850 | —Not posted · NCT06939296 |
| Weight loss of 5% or more | —Trial running · NCT07311850 | —Not posted · NCT06939296 |
| Weight loss of 10% or more | —Trial running · NCT07311850 | —Not posted · NCT06939296 |
| Waist circumference, change (cm) | —Trial running · NCT07311850 | —Not posted · NCT06939296 |
Body weight, % change
- Berobenatide
- —Trial running · NCT07311850
- VCT220
- —Not posted · NCT06939296
Weight loss of 5% or more
- Berobenatide
- —Trial running · NCT07311850
- VCT220
- —Not posted · NCT06939296
Weight loss of 10% or more
- Berobenatide
- —Trial running · NCT07311850
- VCT220
- —Not posted · NCT06939296
Waist circumference, change (cm)
- Berobenatide
- —Trial running · NCT07311850
- VCT220
- —Not posted · NCT06939296
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Berobenatide
Developed by Pfizer
NCT06897202 · Phase 2 · completed
The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.
Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT07400653 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Day 197) (Baseline (Week 0) through Week 28 (Day 197)): Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
Result source: NCT06897202
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07340320 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | VCT220 |
|---|---|---|
| HbA1c, change | —Trial running · NCT07400653 | —Not reported |
| Body weight, change (kg) | —Trial running · NCT07400653 | —Not reported |
| HbA1c below 7% | —Trial running · NCT07400653 | —Not reported |
| Fasting plasma glucose, change | —Trial running · NCT07400653 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07400653 | —Not reported |
HbA1c, change
- Berobenatide
- —Trial running · NCT07400653
- VCT220
- —Not reported
Body weight, change (kg)
- Berobenatide
- —Trial running · NCT07400653
- VCT220
- —Not reported
HbA1c below 7%
- Berobenatide
- —Trial running · NCT07400653
- VCT220
- —Not reported
Fasting plasma glucose, change
- Berobenatide
- —Trial running · NCT07400653
- VCT220
- —Not reported
3-point MACE (% with event)
- Berobenatide
- —Trial running · NCT07400653
- VCT220
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
VCT220: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · VCT220's landscape